FERGUSON STRATEGIES, LLC for CELGENE CORPORATION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Policy issues regarding the U.S.-China Joint Commission on Commerce and Trade, including Article 26.3 of Chinese Patent Law and biopharmaceutical intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM HIGGINS | — |
| CHRIS JONES | — |
Health Issues HCR
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Prescription Drug User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues. Public Law No. 110-85, the "Food and Drug Administration Amendments Act," including current policy issues relating to FDA's Risk Evaluation and Mitigation Strategy authority. H.R. 3230, the "Veterans' Access To Care Through Choice, Accountability and Transparency Act." H.R. 3116, the "Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act." Policy issues relating to orphan drugs and medicines for rare diseases.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM HIGGINS | — |
| CHRIS JONES | — |
Veterans VET
H.R. 3230, the "Veterans' Access to Care through Choice, Accountability and Transparency Act."
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM HIGGINS | — |
| CHRIS JONES | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.